GENERAL ATLANTIC L.P. 13D/13G Filings for Akero Therapeutics, Inc. (AKRO)

GENERAL ATLANTIC L.P. 13D and 13G filings for Akero Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		 Transaction
Date		 Type Company
Symbol		 Filed By
Symbol		 Shares Owned
% Owned		 Shares Vs. Prev Report View
2025-05-15
08:13 am
Purchase		 2025-03-31 13G Akero Therapeutics, Inc.
AKRO		 GENERAL ATLANTIC L.P. 6,796,489
8.400%		 1,562,500increase
(+29.85%)		 Filing
2024-03-15
10:08 am
Purchase		 2024-03-06 13G Akero Therapeutics, Inc.
AKRO		 GENERAL ATLANTIC L.P. 5,233,989
7.700%		 5,233,989increase
(New Position)		 Filing